{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:50:31Z","timestamp":1754153431631,"version":"3.41.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1136\/ijgc-2021-003210","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:55:47Z","timestamp":1655898947000},"page":"1258-1265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-4038","authenticated-orcid":false,"given":"Nataliya","family":"Moldovan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldrich","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-4910","authenticated-orcid":false,"given":"Alon D","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-003210_bb0010","unstructured":"Canadian Cancer Statistics 2019 . Canadian Cancer Society, Statistics Canada, Public Health Agency of Canada, Provincial\/Territorial Cancer Registries. cancer.ca\/statistics."},{"key":"10.1136\/ijgc-2021-003210_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"year":"2018","author":"Canadian Cancer Statistics Advisory Committee","key":"10.1136\/ijgc-2021-003210_bb0020"},{"key":"10.1136\/ijgc-2021-003210_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-003210_bb0030","unstructured":"National Comprehensive Cancer Network . NCCN guideline uterine neoplasms (version 1.2022)."},{"key":"10.1136\/ijgc-2021-003210_bb0035","first-page":"S1","article-title":"The role of postoperative radiation therapy for endometrial cancer: an ASTRO evidence-based guideline","author":"Klopp","year":"2014","journal-title":"Practical Radiation Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0090-8258(80)90096-7","article-title":"Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment","volume":"10","author":"Kinsella","year":"1980","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.brachy.2019.05.003","article-title":"Vaginal brachytherapy alone for patients with stage II endometrial cancer with inner half cervical stromal invasion","volume":"18","author":"Barnes","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1136\/ijgc-2021-003210_bb0050","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0055","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"The Lancet"},{"key":"10.1136\/ijgc-2021-003210_bb0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2021-003210_bb0065","first-page":"235","article-title":"Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma","volume":"99","author":"Horowitz","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2021-003210_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/gyno.2001.6276","article-title":"Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy","volume":"82","author":"Fanning","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/gyno.2001.6130","article-title":"Postoperative vaginal vault brachytherapy for node-negative stage II (occult) endometrial carcinoma","volume":"81","author":"Ng","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2005.04.030","article-title":"Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors","volume":"98","author":"Rittenberg","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2008.12.029","article-title":"Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma","volume":"113","author":"Cannon","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.brachy.2017.10.011","article-title":"The impact of adjuvant vaginal brachytherapy in women with stage II uterine endometrioid carcinoma: results of a national cancer database analysis","volume":"17","author":"Lee","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1136\/ijgc-2021-003210_bb0095","first-page":"383","article-title":"Radiation therapy improves disease-specific survival in women with stage II endometrioid endometrial cancer\u2014Brachytherapy may be sufficient","volume":"17","author":"Nwachukwu","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2018.04.049","article-title":"Multi-Institutional analysis of vaginal brachytherapy alone for women with stage II endometrial carcinoma","volume":"101","author":"Harkenrider","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2021-003210_bb0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.brachy.2018.02.001","article-title":"The role of radiation therapy in the treatment of stage II endometrial cancer: A large database study","volume":"17","author":"Wojcieszynski","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1136\/ijgc-2021-003210_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ygyno.2017.08.021","article-title":"Outcomes of stage II endometrial cancer: the UPMC Hillman Cancer Center experience","volume":"147","author":"Chen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2014.12.012","article-title":"Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study","volume":"136","author":"Elshaikh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2014.04.008","article-title":"Adjuvant treatment and analysis of failures in patients with high-risk FIGO stage IB-II endometrial cancer: an Italian multicenter retrospective study (CTF study)","volume":"134","author":"Gadducci","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.brachy.2015.02.196","article-title":"Adjuvant radiotherapy in stage II endometrial carcinoma: is brachytherapy alone sufficient for local control?","volume":"14","author":"Paydar","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1136\/ijgc-2021-003210_bb0130","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ijgc-2019-000317","article-title":"Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer","volume":"29","author":"Jin","year":"2019","journal-title":"Int J Gynecol Cancer"},{"journal-title":"cmprsk: Subdistribution analysis of competing risks. R package version 2.2-10","year":"2020","author":"Gray","key":"10.1136\/ijgc-2021-003210_bb0135"},{"journal-title":"A package for survival analysis in R. R package version 3.2-7","year":"2020","author":"Therneau","key":"10.1136\/ijgc-2021-003210_bb0140"},{"journal-title":"survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.8","year":"2020","author":"Kassambara","key":"10.1136\/ijgc-2021-003210_bb0145"},{"year":"2015","author":"STATACorp","key":"10.1136\/ijgc-2021-003210_bb0150"},{"key":"10.1136\/ijgc-2021-003210_bb0155","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in High-Intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0160","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2021-003210_bb0165","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2021-003210_bb0170","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.2147\/CMAR.S202628","article-title":"An integrated prediction model of recurrence in endometrial endometrioid cancers","volume":"11","author":"Miller","year":"2019","journal-title":"Cancer Manag Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24006881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24006881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-003210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:27:04Z","timestamp":1753234024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24006881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1048891X24006881"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-003210","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-003210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}